机构：[1]Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing, China[2]Sichuan Provincial People’s Hospital, Sichuan Medical Science Academy, Chengdu, China四川省人民医院[3]Suzhou Municipal Hospital, Suzhou, China[4]Women’s Hospital School of Medicine, Zhejiang University, Hangzhou, China[5]Second Affiliated Hospital Wen Zhou Medical College, Wenzhou, China[6]Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China[7]People’s Hospital Peking University, Beijing, China[8]Southwest Hospital, Army Medical University, Chongqing, China[9]Shanghai Ruijin Hospital, College of Medicine, Shanghai Jiao Tong University, Shanghai, China[10]Peking University Cancer Hospital, Beijing, China[11]Xuanwu Hospital Capital Medical University, Beijing, China首都医科大学宣武医院普通外科[12]Affiliated Hospital of Nantong University, Nantong, China[13]Cancer Hospital of Shantou University Medical College, Shantou, China[14]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China[15]Huadong Hospital Affiliated to Fudan University, Shanghai, China
IntroductionAdjuvant docetaxel-based chemotherapy is frequently used in the treatment of operable early breast cancer (EBC). This study investigated patterns of docetaxel use in patients with EBC in real-world clinical practice in China.MethodsThis was a multicenter, prospective, observational study of Chinese women with operable breast cancer in tier 1 non-oncology-specific hospitals and other city hospitals in China. Adult Chinese female patients (18years) with newly diagnosed breast cancer who underwent surgery and received docetaxel-containing adjuvant chemotherapy were eligible for inclusion. The primary end point of the study was to assess patterns of docetaxel use for adjuvant therapy in Chinese clinical practice. Secondary end points included factors associated with treatment selection, patterns of G-CSF use and safety.ResultsIn total, 502 patients were enrolled, 475 of whom were included in the analysis. The results showed that 31.6% of patients received docetaxel and anthracyclines in combination, 47.2% received docetaxel and anthracyclines sequentially, 18.5% received docetaxel and other medication either in combination or sequentially and 2.7% received other' chemotherapy regimens. Factors influencing selection of docetaxel/anthracycline in combination versus sequentially included age, breast cancer subgroup, PR status, and preoperative neoadjuvant chemotherapy. A total of 258 (54.3%), 35 (7.4%), and 108 (22.7%) patients received G-CSF as primary prevention, secondary prevention and treatment, respectively. Treatment-emergent adverse events (TEAEs) occurred in 54.5% (259) of patients, and the most frequently reported TEAEs (5% of patients) included bone marrow failure (10.1%), granulocytopenia (9.9%), nausea (8.8%) and vomiting (6.9%). Neutropenia and febrile neutropenia were reported by 10 and 12 patients, respectively.ConclusionDocetaxel for adjuvant chemotherapy of operable EBC in China was most commonly given in combination or sequentially with anthracyclines. The study also showed that in China G-CSF is most frequently used as primary prophylactic, and no unexpected safety events were observed during docetaxel treatment.FundingSanofi (China).
基金：
Funding: Sanofi (China).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区药学
最新[2023]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区药学
JCR分区：
出版当年[2017]版：
Q2PHARMACOLOGY & PHARMACYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2PHARMACOLOGY & PHARMACY
第一作者机构：[1]Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing, China
通讯作者：
通讯机构：[1]Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing, China
推荐引用方式(GB/T 7714)：
H. Xie,S. Wang,J. Liu,et al.Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study[J].ADVANCES IN THERAPY.2019,36(1):131-146.doi:10.1007/s12325-018-0841-7.
APA：
H. Xie,S. Wang,J. Liu,S. Yu,Y. Chen...&A. Cheng.(2019).Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.ADVANCES IN THERAPY,36,(1)
MLA：
H. Xie,et al."Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study".ADVANCES IN THERAPY 36..1(2019):131-146
